Browsing by Author "Aras O."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Aetiological factors of bladder cancer in the Aegean Region of Turkey between the years 1985-1996
    (1999) Gümüş B.; Aras O.; Ateşci Y.Z.; Müezzinoǧlu T.
    A great majority of urological cases are bladder tumours. The purpose of this study is to bring out the aetiological factors related to bladder tumours. The parameters such as age, sex, profession, age at tumour occurrence, smoking, drinking habits, such as the level of consumption of tea and coffee, and accompanying urological diseases were evaluated. Three hundred and forty-seven patients with bladder tumours were included in this study. Of them 332 (95.6%) were males and 15 (4.4%) females. The average age was 62.1 (22-87) years. Of the patients 326 (93.9%) smoked, 175 (50.4%) lived in cities and the other 49.6% lived in the countryside. Of the tumours 89.9% were transitional cell carcinomas. In conclusion, bladder tumours are closely related to consumption of tobacco factors and profession. The risk of tumour development increases progressively in people who are exposed to industrial agents and agricultural chemicals.
  • No Thumbnail Available
    Item
    Multifunctional molecular imaging probes for estrogen receptors: 99mTc labeled diethylstilbestrol (DES) conjugated, cuinp quantum dot nanoparticles (DESCIP)
    (Springer Netherlands, 2017) Moharrami P.; Unak P.; Guldu O.K.; Medine E.I.; Gumuser G.; Bilgin E.S.; Aras O.
    A theranostic nanoparticle was synthesized based on diethylstilbestrol conjugated with phosphate, copper, and indium (DESCIP) and labelled with 99mTc which can be used for SPECT imaging of ER-enriched cancers. In vitro biological activity of 99mTc-DESCIP was examined in breast adenocarcinoma cells (MCF-7), prostatic carcinoma cells (PC-3), and pulmonary epithelial cells (A-549). In vivo lymph node imaging was performed in normal and receptor blocked female New Zealand rabbits. Results demonstrated that 99mTc-DESCIP and DESCIP has potential for imaging ER-enriched tumors such as breast and prostate tumors, and their metastases in the lung, as well as improving management for their therapies. © 2017, Akadémiai Kiadó, Budapest, Hungary.
  • No Thumbnail Available
    Item
    The radiolabeling of [161Tb]Tb-PSMA-617 by a novel radiolabeling method and preclinical evaluation by in vitro/in vivo methods
    (Akademiai Kiado ZRt., 2024) Uygur E.; Sezgin C.; Parlak Y.; Karatay K.B.; Arıkbaşı B.; Avcıbaşı U.; Toklu T.; Barutça S.; Harmanşah C.; Sözen T.S.; Maus S.; Scher H.; Aras O.; Gümüşer F.G.; Biber Muftuler F.Z.
    Prostate cancer (PC) is the most prevalent cancer in elderly men, exhibiting a positive correlation with age. As resistance to treatment has developed, particularly in the progressive stage of the disease and in the presence of microfocal multiple bone metastases, new generation radionuclide therapies have emerged. Recently introduced for treating micrometastatic foci, Terbium-161 ([161Tb]) has shown great promise in prostate cancer treatment. This study investigated the in vitro and in vivo cytotoxicity of Terbium-161 ([161Tb])-radiolabeled prostate-specific membrane antigen (PSMA)-617. [161Tb]Tb-PSMA-617 (7.4 MBq/nmol) demonstrated a radiochemical yield of 97.99 ± 2.01% and hydrophilicity. [161Tb]Tb-PSMA-617 was also shown to have good stability, with a radiochemical yield of over 95% up to 72 h. In vitro, [161Tb]Tb-PSMA-617 exhibited cytotoxicity on LNCaP cells but not on PC3 cells. In vivo, scintigraphy imaging visualized the accumulation of [161Tb]Tb-PSMA-617 in the prostate, kidneys, and bladder. The results suggest that [161Tb]Tb-PSMA-617 can be an effective radiolabeled agent for the treatment of PSMA positive foci in prostate cancer. © Akadémiai Kiadó, Budapest, Hungary 2024.